KYBORA’s Key Takeaways from BIO International 2026: Navigating Cautious Optimism An Industry at an Inflection Point The Rise of Chinese Biopharma MFN Pricing Reshapes the Ex-US Calculus Capital Is Returning, Driven by the Patent Cliff AI Is Permeating the Value
Most late-stage biopharma deals do not die because of one bad clause. They die because a problem that was visible earlier was never forced into the open. Here’s what that looks like, and why the strategic partner is never one
In biopharma, signing the deal is just the end of the beginning, not the finish line. For a license or a partnership, a signed agreement can still become a failed one. Here’s what it takes to close a deal that
